+1.61%
Today
Loading 1D prices…
Company profile
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety in the United States. The company's lead product candidate is CTx-1301 (dexmethylphenidate), which is in Phase 3 clinical trials for the treatment of ADHD in children, adolescents, and adults. It also develops CTx-2103 (buspirone), which is in a formulation stage for the treatment of anxiety. In addition, the company plans to initiate a clinical plan for CTx-1302 (dextroamphetamine) to treat ADHD. Cingulate Inc. was founded in 2012 and is headquartered in Kansas City, Kansas.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
KANSAS CITY, KS, United States
Employees
14
Fiscal year end
1231
CIK
1862150
Session & valuation
Latest annual period
Deterministic peer set
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| ALDXAldeyra Therapeutics Inc. Common Stock | $73.6M | $0.00 | — | -$0.56 | -9.63% | Buy |
| MAIAMAIA Biotechnology Inc. Common Stock | $75.1M | $0.00 | — | -$0.70 | -7.20% | Buy |
| SPROSpero Therapeutics Inc. Common Stock | $71.6M | $12.6M | +68.11% | $0.15 | -0.79% | Buy |
| VRCAVerrica Pharmaceuticals Inc. Common Stock | $75.8M | $35.6M | -50.31% | -$1.68 | -5.63% | Buy |
| PMVPPMV Pharmaceuticals Inc. Common Stock | $70.8M | $0.00 | — | -$1.48 | -2.19% | Buy |